Key Segmentation:
By Application
-
Diagnostics
-
Therapeutics
By Product
-
Enzymes
-
Kits and Reagents
-
Guide RNA
-
Other Products
By End User
-
Pharmaceutical Companies and Biotechnology Companies
-
Academics and Government Research Institutes
-
Other End Users
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Leading companies include Mammoth Biosciences, Sherlock Biosciences, Intellia Therapeutics, Thermo Fisher Scientific, Merck KGaA, Caribou Biosciences, Editas Medicine, CRISPR Therapeutics, and Beam Therapeutics, among others.
Key opportunities include instrument-free CRISPR diagnostics for underserved regions, increased funding for HIV and tuberculosis gene-editing therapies, and expansion across Asia Pacific’s biotechnology infrastructure.
Growth is primarily driven by the rising global prevalence of infectious diseases and continued advancements in CRISPR-Cas systems that improve the specificity, speed, and cost-effectiveness of diagnostic and therapeutic applications.
By Application, Diagnostics dominates the market with approximately 58.40% share in 2025, supported by the accuracy and rapidity of CRISPR/Cas12 and CRISPR/Cas13-based point-of-care testing platforms.
North America dominates the market with approximately 41.20% share in 2025, supported by a strong research and development environment and significant government funding for CRISPR-based innovation.
